City of Hope Patient Forum this Saturday and IVIG and immunoglobulins in CLL (chronic lymphocytic leukemia)
Labels: Chronic lymphocytic leukemia, City of Hope, CLL, CLL support group, http://cllsociety.org, IGG immunoglobulins IVIG, IVIG
What started as a personal journey of a doctor turned patient morphed into a way to share what’s universal in dealing with cancer, in my case a nasty leukemia (CLL), a failed transplant and a successful clinical trial. The telling of my journey has become a journey to teach about CLL, related blood issues and all cancers. Please visit our new website http://cllsociety.org for the latest news and information. Smart patients get smart care™. If you want to reach me, email bkoffmanMD@gmail.com
Labels: Chronic lymphocytic leukemia, City of Hope, CLL, CLL support group, http://cllsociety.org, IGG immunoglobulins IVIG, IVIG
Labels: ACP-196, Chronic lymphocytic leukemia, CLL, ibrutinib, IGG immunoglobulins IVIG, ITP, IVIG
Labels: ALC, CBC, good news, IGG immunoglobulins IVIG, IVIG, lab results, neutrophils, OSU, uric acid
Labels: alemtuzumab, Andrew Schorr Patient, ASCO 2013, CAR-T, Dr. Wierda, GA-101, HDMP, IGG immunoglobulins IVIG, immunity, immunotherapy, Lenalidomide, obinutuzumab, ofatumumab, Patient Power, T cells
Vaccines, Blood & Biologics
FDA Safety Communication: New boxed warning for thrombosis related to human immune globulin products. Date: June 10, 2013 Purpose: FDA has analyzed recent data that has strengthened the association between the use of intravenous, subcutaneous and intramuscular human immune globulin products and the risk of thrombosis. Additional caution regarding the use of these products is warranted. Summary of Safety Issue 1 Recommendations for Patients 2 Recommendations for Health Professionals 3 Summary of Safety Issue The U.S. Food and Drug Administration (FDA) is requiring manufacturers to add information on thrombosis to th current boxed warning in the labels of all intravenous human immune globulin products and to add a boxed warning to the labels of all subcutaneous and intramuscular human immune globulin products to highlight the risk of thrombosis and to add information on its mitigation. A retrospective analysis of data from a large health claims-related database, as well as continued postmarketing adverse event reports of thrombosis have strengthened the evidence for an association between the use of intravenous, subcutaneous, and intramuscular human immune globulin products and the risk of thrombosis. This information necessitates a boxed warning for the entire class of products. Human immune globulin products are used in a variety of conditions, both on and off-label, by healthcare professionals who may not be aware of the thrombosis risk and measures that could be taken to mitigate this risk. Although all human immune globulin products already contain some information related to the risk of thrombosi in the current WARNINGS and PRECAUTIONS sections of their labels, FDA recognizes that the communication of this risk and its mitigation are not standardized. FDA proposes that for thrombosis a more prominent placement of risk information and a uniform approach for communicating the risk and its possible mitigation will help to reduce the occurrence of these serious adverse events. The information on thrombosis in the boxed warning states: Thrombosis may occur regardless of the route of administration. Risk factors include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer at the minimum concentration available and at the minimum rate of infusion practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Recommendations for Patients Patients should be aware of this risk and discuss this risk with their healthcare professionals. Be aware that thrombosis is associated with human immune globulin products. Talk to your healthcare professional about any risk factors or concerns you may have with human immune globulin products. Contact your healthcare professional if you develop any signs or symptoms of thrombosis during or after receiving human immune globulin. Signs or symptoms of thrombosis may include: pain and/or swelling of an arm or leg with warmth over the affected area discoloration of an arm or leg unexplained shortness of breath |
Labels: adverse events, clots, FDA, IGG immunoglobulins IVIG, ITP
Labels: ibrutinib, IGG immunoglobulins IVIG, ITP, veins
Labels: ciclosporin, IGG immunoglobulins IVIG, MRI, nodes, plan, Rituximab maintenance
Labels: IGG immunoglobulins IVIG, ITP, splenectomy
Labels: IGG immunoglobulins IVIG, infusion
Labels: cancel infusion, IGG immunoglobulins IVIG
Labels: IGG immunoglobulins IVIG